Aratana Therapeutics (PETX) : Traders are bullish on Aratana Therapeutics (PETX) as it has outperformed the S&P 500 by a wide margin of 39.36% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 12.11%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12.18% in the last 1 week, and is up 40.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 26.49% and the 50-Day Moving Average is 35.92%. Aratana Therapeutics (NASDAQ:PETX): stock turned positive on Friday. Though the stock opened at $8.99, the bulls momentum made the stock top out at $9.652 level for the day. The stock recorded a low of $8.99 and closed the trading day at $9.49, in the green by 5.92%. The total traded volume for the day was 1,161,562. The stock had closed at $8.96 in the previous days trading.
The company Insiders own 6.7% of Aratana Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -17.88% . Institutional Investors own 83.16% of Aratana Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -17.88%. Also, Equity analysts at the Brokerage firm Barclays maintains its rating on Aratana Therapeutics (NASDAQ:PETX). The rating major has initiated the coverage with overweight rating on the shares. The Analysts at Barclays lowers the price target from $15 per share to $11 per share. The rating by the firm was issued on August 11, 2016.
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both. The Companys target indications include pain and inflammation associated with osteoarthritis, inappetence, post-operative pain, lymphoma, osteosarcoma, atopic dermatitis, ocular herpes and feline immunodeficiency virus. The Companys most advanced products from a development and commercialization perspective, AT-004 and AT-005, are monoclonal antibodies (MAbs) for treating lymphoma in dogs.